Skip to main content
Erschienen in: Angiogenesis 1/2018

17.11.2017 | Original Paper

Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA)

verfasst von: Karthik Reddy Kami Reddy, Chandrashekhar Dasari, Divya Duscharla, Bhukya Supriya, N. Sai Ram, M. V. Surekha, Jerald Mahesh Kumar, Ramesh Ummanni

Erschienen in: Angiogenesis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Tissue microarray analysis confirmed higher dimethylarginine dimethylaminohydrolase-1 (DDAH1) expression in prostate cancer (PCa) compared to benign and normal prostate tissues. DDAH1 regulates nitric oxide (NO) production by degrading endogenous nitric oxide synthase (NOS) inhibitor, asymmetric dimethylarginine (ADMA). This study examined whether DDAH1 has any physiological role in PCa progression. Using overexpression of DDAH1 in PCa (PC3 and LNCaP) cell lines, we found that DDAH1 promotes cell proliferation, migration and invasion by lowering ADMA levels, as well as increasing NO production. VEGF, HIF-1α and iNOS were upregulated in DDAH1 expressing cells as result of elevated NO. DDAH1 increased secretion of pro-angiogenic signals bFGF and IL-8, into conditioned media. Treatment of DDAH1-positive PCa cells with NOS inhibitors (L-NAME and 1400 W) attenuated DDAH1 activity to promote cell growth. Xenografts derived from these cells grew significantly faster (> twofold) than those derived from control cells. Proliferation rate of cells stably expressing mutant DDAH1 was same as control cells unlike wild-type DDAH1-positive PCa cells. Xenograft tumors derived from mutant-positive cells did not differ from control tumors. VEGF, HIF-1α and iNOS expression did not differ in DDAH1 mutant-positive tumors compared to control tumors, but was upregulated in wild-type DDAH1 overexpressing tumors. Furthermore, CD31 immunostaining on xenograft tissues demonstrated that DDAH1 tumors had high endothelial content than mutant DDAH1 tumors. These data suggest that DDAH1 is an important mediator of PCa progression and NO/DDAH pathway needs to be considered in developing therapeutic strategies targeted at PCa.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2):327–336CrossRefPubMed Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2):327–336CrossRefPubMed
2.
Zurück zum Zitat Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79(2):1825–188CrossRef Fidler IJ, Ellis LM (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79(2):1825–188CrossRef
7.
Zurück zum Zitat Ziche M (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance. J Clin Invest 94:2036–2044CrossRefPubMedPubMedCentral Ziche M (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance. J Clin Invest 94:2036–2044CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F, Walther R (2008) Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266(2):171–185CrossRefPubMed Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F, Walther R (2008) Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266(2):171–185CrossRefPubMed
19.
21.
23.
Zurück zum Zitat Monteiro HP, Gruia-Gray J, Peranovich TMS, De Oliveira LCB, Stern A (1999) Nitric oxide stimulates tyrosine phosphorylation of focal adhesion kinase, SRC kinase, and mitogen-activated protein kinases in murine fibroblasts. Free Radic Biol Med 28(2):174–182CrossRef Monteiro HP, Gruia-Gray J, Peranovich TMS, De Oliveira LCB, Stern A (1999) Nitric oxide stimulates tyrosine phosphorylation of focal adhesion kinase, SRC kinase, and mitogen-activated protein kinases in murine fibroblasts. Free Radic Biol Med 28(2):174–182CrossRef
24.
Zurück zum Zitat Figel S (2011) Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anti-Cancer Agents Med Chem 11:607–616CrossRef Figel S (2011) Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anti-Cancer Agents Med Chem 11:607–616CrossRef
25.
Zurück zum Zitat Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P (2003) Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 308(4):984–989CrossRefPubMed Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P (2003) Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 308(4):984–989CrossRefPubMed
26.
30.
Zurück zum Zitat Faton (2002) Role of nitric oxide in the regulation hif1a during hypoxia. Am J Physiol Cell Physiol 283:C178–C186CrossRef Faton (2002) Role of nitric oxide in the regulation hif1a during hypoxia. Am J Physiol Cell Physiol 283:C178–C186CrossRef
35.
Zurück zum Zitat Varner JA, Cheresh DA (1996) Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 69–87 Varner JA, Cheresh DA (1996) Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 69–87
36.
Zurück zum Zitat Figel S, Gelman IH (2011) Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anticancer Agents Med Chem 11(7):607–616CrossRefPubMed Figel S, Gelman IH (2011) Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anticancer Agents Med Chem 11(7):607–616CrossRefPubMed
40.
Zurück zum Zitat Trojan L, Thomas D, Friedrich D, Grobholz R, Knoll T, Alken P, Michel MS (2004) Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation. Anticancer Res 24(3a):1651–1656PubMed Trojan L, Thomas D, Friedrich D, Grobholz R, Knoll T, Alken P, Michel MS (2004) Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation. Anticancer Res 24(3a):1651–1656PubMed
41.
42.
Zurück zum Zitat Mukherji D, Temraz S, Wehbe D, Shamseddine A (2013) Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol 87(2):122–131CrossRefPubMed Mukherji D, Temraz S, Wehbe D, Shamseddine A (2013) Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol 87(2):122–131CrossRefPubMed
43.
Zurück zum Zitat Fu W, Madan E, Yee M, Zhang H (2012) Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta (BBA) Rev Cancer 1825(2):140–152CrossRef Fu W, Madan E, Yee M, Zhang H (2012) Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta (BBA) Rev Cancer 1825(2):140–152CrossRef
Metadaten
Titel
Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA)
verfasst von
Karthik Reddy Kami Reddy
Chandrashekhar Dasari
Divya Duscharla
Bhukya Supriya
N. Sai Ram
M. V. Surekha
Jerald Mahesh Kumar
Ramesh Ummanni
Publikationsdatum
17.11.2017
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 1/2018
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-017-9587-0

Weitere Artikel der Ausgabe 1/2018

Angiogenesis 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.